US WorldMeds: Norgine and US WorldMeds enter into exclusive agreement to commercialise eflornithine

Norgine and US WorldMeds (USWM) announced an exclusive licensing agreement by which Norgine will register and commercialise difluoromethylornithine, DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand. DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblast...